27 96
[37]
Grotenhuis AJ, Ebben CW, Aben KK, et al. The effect of smoking and timing of smoking cessation on clinical outcome in non–muscle- invasive bladder cancer. Urol Oncol 2015;33:65.e9–65.e17.
[38]
Hwang EC, Kim YJ, Hwang IS, et al. Impact of diabetes mellitus on recurrence and progression in patients with non–muscle invasive bladder carcinoma: a retrospective cohort study. Int J Urol 2011; 18:769–76.
[39]
Kashif Khan M, Ahmed I, Raza SJ. Factors effecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG. Pak J Med Sci 2014;30:326–30.
[40]
Lammers RJM, Witjes WPJ, Hendricksen K, Caris CTM, Janzing- Pastors MHC, Witjes JA. Smoking status is a risk factor for recur- rence after transurethral resection of non–muscle-invasive bladder cancer. Eur Urol 2011;60:713–20.[41]
Rausch S, Hennenlotter J, Todenho¨fer T, et al. Impaired estimated glomerular filtration rate is a significant predictor for non–muscle- invasive bladder cancer recurrence and progression—introducing a novel prognostic model for bladder cancer recurrence. Urol Oncol 2014;31:1178–83.[42]
Rink M, Xylinas E, Babjuk M, et al. Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer. J Urol 2012;188:2120–7.[43]
Rink M, Furberg H, Zabor EC, et al. Impact of smoking and smoking cessation on oncologic outcomes in primary non–muscle-invasive bladder cancer. Eur Urol 2013;63:724–32.[44]
Serretta V, Altieri V, Morgia G, et al. Cigarette smoking status at diagnosis and recurrence in intermediate-risk non–muscle- invasive bladder carcinoma. Urology 2013;81:277–82.[45]
Sfakianos JP, Shariat SF, Favaretto RL, Rioja J, Herr HW. Impact of smoking on outcomes after intravesical bacillus Calmette-Gue´rin therapy for urothelial carcinoma not invading muscle of the blad- der. BJU Int 2011;108:526–30.[46]
Wyszynski A, Tanyos SA, Rees JR, et al. Body mass and smoking are modifiable risk factors for recurrent bladder cancer. Cancer 2014; 120:408–14.
[47]
Cheng L, Neumann RM, Weaver AL, Spotts BE, Bostwick DG. Pre- dicting cancer progression in patients with stage T1 bladder carci- noma. J Clin Oncol 1999;17:3182–7.[48]
Segal R, Yafi FA, Brimo F, Tanguay S, Aprikian A, Kassouf W. Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy? BJU Int 2012;109:1026–30.
[49]
Rink M, Xylinas E, Trinh Q-D, et al. Gender-specific effect of smok- ing on upper tract urothelial carcinoma outcomes. BJU Int 2013; 112:623–37.[50]
Rink M, Xylinas E, Babjuk M, et al. Smoking reduces the efficacy of intravesical bacillus Calmette-Gue´rin immunotherapy in non– muscle-invasive bladder cancer. Eur Urol 2012;62:1204–6.[51]
Xylinas E, Kent M, Kluth L, et al. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non– muscle-invasive urothelial carcinoma of the bladder. Br J Cancer 2013;109:1460–6.
[52]
Figueroa JD, Han SS, Garcia-Closas M, et al. Genome-wide interac- tion study of smoking and bladder cancer risk. Carcinogenesis 2014;35:1737–44.[53]
Baumann BC, Guzzo TJ, He J, et al. A novel risk stratification to predict local-regional failures in urothelial carcinoma of the bladder after radical cystectomy. Int J Radiat Oncol Biol Phys 2013;85:81–8.[54]
Boorjian SA, Kim SP, Weight CJ, Cheville JC, Thapa P, Frank I. Risk factors and outcomes of urethral recurrence following radical cystectomy. Eur Urol 2011;60:1266–72.[55]
Bostro¨m PJ, Alkhateeb S, Trottier G, et al. Sex differences in bladder cancer outcomes among smokers with advanced bladder cancer. BJU Int 2012;109:70–6.[56]
Kim PH, Kent M, Zhao P, et al. The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. World J Urol 2014;32: 453–9.[57]
Lee C, Kim KH, You D, et al. Smoking and survival after radical cystectomy for bladder cancer. Urology 2012;80:1307–12.[58]
Rink M, Zabor EC, Furberg H, et al. Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. Eur Urol 2013;64:456–64.[59]
Thrasher JB, Frazier HA, Robertson JE, Dodge RK, Paulson DF. Clinical variables which serve as predictors of cancer-specific survival among patients treated with radical cystectomy for transi- tional cell carcinoma of the bladder and prostate. Cancer 1994;73: 1708–15.[60]
Yafi FA, Aprikian AG, Chin JL, et al. Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU Int 2011;108: 539–45.[61]
Gritz ER, Dresler C, Sarna L. Smoking, the missing drug interaction in clinical trials: ignoring the obvious. Cancer Epidemiol Biomark- ers Prev 2005;14:2287–93.[62]
Rink M, Shariat SF. Re: Global effects of smoking, of quitting, and of taxing tobacco. Eur Urol 2014;66:176–8.
[63]
Sosnowski R, Przewozniak K. The role of the urologist in smoking cessation: why is it important? Urol Oncol 2015;33:30–9.[64]
Guzzo TJ, Hockenberry MS, Mucksavage P, Bivalacqua TJ, Schoenberg MP. Smoking knowledge assessment and cessation trends in patients with bladder cancer presenting to a tertiary referral center. Urology 2012;79:166–71.[65]
Bassett JC, Gore JL, Chi AC, et al. Impact of a bladder cancer diagnosis on smoking behavior. J Clin Oncol 2012;30:1871–8.[66]
Kowalkowski MA, Goltz HH, Petersen NJ, Amiel GE, Lerner SP, Latini DM. Educational opportunities in bladder cancer: increasing cysto- scopic adherence and the availability of smoking-cessation pro- grams. J Cancer Educ 2014;29:739–45.[67]
Strope SA, Montie JE. The causal role of cigarette smoking in bladder cancer initiation and progression, and the role of urologists in smoking cessation. J Urol 2008;180:31–7.[68]
Fajkovic H, Halpern JA, Cha EK, et al. Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol 2011;29: 457–63.
[69]
Rink M, Lee DJ, Kent M, et al. Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. BJU Int 2013; 111:E30–6.
[70]
Rink M, Shariat SF. Can we apply nomograms derived in the United States to European patients? Yes we can! Eur Urol 2012;61:65–6.[71]
Shariat SF, Karakiewicz PI, Palapattu GS, et al. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res 2006;12:6663–76.
[72]
Shariat SF, Rink M, Ehdaie B, et al. Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy. Eur Urol 2013;63:371–8.
[73]
Rink M, Cha EK, Green D, et al. Biomolecular predictors of urothelial cancer behavior and treatment outcomes. Curr Urol Rep 2012; 13:122–35.
[74]
Wang LC, Xylinas E, Kent MT, et al. Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. Urol Oncol 2014;32:433–40.
E U R O P E A N
U R O L O G Y
F O C U S
1
( 2 0 1 5
)
1 7 – 2 7
27